Thyroid cancer is among the most common malignancies in the US, with a 3.6% annual increase in incidence over the past 50 years.1 Treatment regimens for thyroid cancer are well-established, with excellent survival outcomes. However, costs of thyroid cancer care can vary substantially by hospital and impose significant financial burdens on patients2; among patients with cancer, bankruptcy rates are highest for those with thyroid cancer.3
Xiao R, Rathi VK, Gross CP, Ross JS, Sethi RKV. Payer-Negotiated Prices in the Diagnosis and Management of Thyroid Cancer in 2021. JAMA. 2021;326(2):184–185. doi:10.1001/jama.2021.8535
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: